학술논문

A Phase 2, randomized, placebo-controlled, 24-Week study of the efficacy and safety of losmapimod in treating subjects with FSHD: ReDUX4
Document Type
Journal
Source
NEUROMUSCULAR DISORDERS; OCT 2020, 30 pS112-pS112, 1p. Supplement: 1
Subject
Language
English
ISSN
18732364